News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
887,979 Results
Type
Article (89098)
Company Profile (555)
Press Release (798309)
Multimedia
Podcasts (254)
Webinars (38)
Section
Business (267173)
Career Advice (4168)
Deals (40059)
Drug Delivery (183)
Drug Development (91848)
Employer Resources (208)
FDA (18637)
Job Trends (17512)
News (399063)
Policy (40028)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (2)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (5)
2027 Biotech Beach Elite (2)
2027 Biotech Beach Standard (3)
2027 Genetown Elite (4)
2027 Genetown Standard (7)
2027 Pharm Country Elite (2)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (7)
Academia (3073)
Academic (2)
Accelerated approval (62)
ADA (50)
Adcomms (43)
Allergies (216)
Alliances (56991)
ALS (249)
Alzheimer's disease (2062)
Antibody-drug conjugate (ADC) (623)
Approvals (19067)
Artificial intelligence (964)
ASCO (345)
Autoimmune disease (406)
Automation (71)
Bankruptcy (409)
Best Places to Work (12634)
BIO (81)
Biologics (1)
BIOSECURE Act (23)
Biosimilars (271)
BioSpace Insights (237)
Biotechnology (336)
Bladder cancer (227)
Brain cancer (87)
Breast cancer (884)
Cancer (7019)
Cardiovascular disease (596)
Career advice (3610)
Career pathing (57)
CAR-T (408)
CDC (77)
Celiac Disease (3)
Cell therapy (1133)
Cervical cancer (60)
Clinical research (79662)
Collaboration (2560)
Commercialization (6)
Company closure (8)
Compensation (1657)
Complete response letters (119)
COVID-19 (3054)
CRISPR (132)
C-suite (1436)
Cystic fibrosis (171)
Data (9262)
Decentralized trials (3)
Denatured (98)
Depression (210)
Dermatology (116)
Diabetes (744)
Diagnostics (7729)
Digital health (77)
Diversity (14)
Diversity, equity & inclusion (49)
Drug discovery (492)
Drug pricing (248)
Drug shortages (39)
Duchenne muscular dystrophy (353)
Earnings (103270)
Editorial (82)
Employer branding (25)
Employer resources (178)
Events (139309)
Executive appointments (1277)
FDA (23083)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (25)
Frontotemporal dementia (37)
Funding (2083)
Gene editing (290)
Generative AI (99)
Gene therapy (894)
GLP-1 (1319)
Government (5577)
Grass and pollen (8)
Guidances (433)
Healthcare (21292)
Hematology (198)
HIV (110)
Huntington's disease (74)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (127)
Immunology and inflammation (381)
Immuno-oncology (126)
Indications (239)
Infectious disease (3474)
Inflammatory bowel disease (249)
Inflation Reduction Act (17)
Influenza (157)
Intellectual property (348)
Interviews (824)
IPO (18032)
IRA (61)
Job creations (5209)
Job search strategy (2876)
JPM (73)
Kidney cancer (27)
Labor market (131)
Layoffs (704)
Leadership (57)
Legal (10174)
Licensing (9)
Liver cancer (112)
Longevity (38)
Lung cancer (931)
Lymphoma (506)
Machine learning (70)
Management (69)
Manufacturing (1361)
Marketing (13)
MASH (234)
Medical affairs (1)
Medical device (15357)
Medtech (15588)
Mergers & acquisitions (23439)
Metabolic disorders (1923)
mRNA (287)
Multiple sclerosis (218)
NASH (24)
Neurodegenerative disease (559)
Neuropsychiatric disorders (137)
Neuroscience (3956)
Neurotech (2)
NextGen: Class of 2026 (7718)
Non-profit (5152)
Now hiring (88)
Obesity (910)
Opinion (385)
Ovarian cancer (260)
Pain (303)
Pancreatic cancer (384)
Parkinson's disease (444)
Partnered (43)
Patents (719)
Patient recruitment (887)
Peanut (73)
People (68391)
Pharmaceutical (81)
Pharmacy benefit managers (38)
Phase 1 (24605)
Phase 2 (34597)
Phase 3 (26020)
Pipeline (11183)
Policy (411)
Postmarket research (3561)
Preclinical (11029)
Press Release (72)
Prostate cancer (371)
Psychedelics (83)
Radiopharmaceuticals (392)
Rare diseases (1401)
Real estate (7467)
Recruiting (83)
Regulatory (30960)
Reports (81)
Research institute (2788)
Resumes & cover letters (655)
Rett syndrome (50)
RNA editing (32)
RSV (101)
Schizophrenia (203)
Series A (355)
Series B (261)
Service/supplier (16)
Sickle cell disease (136)
Special edition (34)
Spinal muscular atrophy (193)
Sponsored (55)
Startups (4379)
State (2)
Stomach cancer (21)
Supply chain (154)
Tariffs (105)
The Weekly (153)
Vaccines (1355)
Venture capital (146)
Weight loss (618)
Women's health (152)
Worklife (25)
Date
Today (71)
Last 7 days (771)
Last 30 days (2507)
Last 365 days (33507)
2026 (20606)
2025 (33213)
2024 (37864)
2023 (42564)
2022 (53928)
2021 (58720)
2020 (57663)
2019 (51334)
2018 (39119)
2017 (37188)
2016 (38329)
2015 (44432)
2014 (39672)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1300)
Alabama (107)
Alaska (7)
Arizona (432)
Arkansas (16)
Asia (52591)
Australia (9250)
California (15205)
Canada (4242)
China (1730)
Colorado (654)
Connecticut (673)
Delaware (468)
Europe (121290)
Florida (2297)
Georgia (493)
Hawaii (5)
Idaho (70)
Illinois (1327)
India (120)
Indiana (702)
Iowa (26)
Japan (658)
Kansas (149)
Kentucky (59)
Louisiana (66)
Maine (93)
Maryland (1824)
Massachusetts (11114)
Michigan (437)
Minnesota (851)
Mississippi (7)
Missouri (173)
Montana (37)
Nebraska (31)
Nevada (161)
New Hampshire (92)
New Jersey (4019)
New Mexico (37)
New York (4009)
North Carolina (2007)
North Dakota (11)
Northern California (7633)
Ohio (480)
Oklahoma (29)
Oregon (48)
Pennsylvania (2964)
Puerto Rico (33)
Rhode Island (55)
South America (1671)
South Carolina (93)
South Dakota (2)
Southern California (6013)
Tennessee (248)
Texas (2476)
United States (54262)
Utah (462)
Vermont (2)
Virginia (382)
Washington D.C. (88)
Washington State (1230)
West Virginia (4)
Wisconsin (169)
Wyoming (2)
887,979 Results for "cell culture company c3".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Novartis receives Health Canada approval for Fabhalta® oral treatment for adults with C3G
May 4, 2026
·
4 min read
Press Releases
Sobi Receives Health Canada Approval for EMPAVELI® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
April 10, 2026
·
5 min read
Press Releases
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)
February 11, 2026
·
3 min read
Policy
C3i Center Inc is First CDMO in Canada to Receive Approval for a Drug Establishment License to Commercially Produce Cell Therapy Drug Products
C3i Center Inc (C3i) announced it has received regulatory approval, in the form of a Drug Establishment License (DEL), to commercially produce cell therapies, making C3i the first CDMO in Canada to achieve this milestone.
June 20, 2024
·
2 min read
Press Releases
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
March 20, 2025
·
16 min read
Press Releases
Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)
March 3, 2025
·
12 min read
Press Releases
Nordic Bioscience announces PRO-C3 launched by Roche Diagnostics on cobas analysers
May 8, 2025
·
2 min read
Press Releases
Eleva administers first dose of its Factor H biological treatment in C3-Glomerulopathy to healthy volunteers
July 7, 2025
·
2 min read
Drug Development
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
Novartis presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta® at the late-breaking clinical trials session of the European Renal Association Congress.
May 25, 2024
·
16 min read
Press Releases
FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
July 29, 2025
·
14 min read
1 of 88,798
Next